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Changes in urinary porphyrin excretion may be the result of hereditary causes and/or from environmental or occupational
exposure. The objective of this study was to measure the amount of some porphyrins in spot urine samples obtained from
volunteers randomly selected from a healthy adult population of São Paulo with a sensitive HPLC method and to estimate normal
ranges for a non-exposed population. Spot urine samples were collected from 126 subjects (both genders, 18 to 65 years old)
not occupationally exposed to porphyrinogenic agents. Porphyrin fractions were separated on RP-18 HPLC column eluted with
a methanol/ammonium acetate buffer gradient, pH 4.0, and measured fluorometrically (excitation 405 nm/emission 620 nm).
The amount of porphyrins was corrected for urinary creatinine excretion. Only 8-carboxyl (uro) and 4-carboxyl (copro) porphyrins
were quantified as μg/g creatinine. Data regarding age, gender, occupational activities, smoking and drinking habits were
analyzed by Mann-Whitney and Kruskal-Wallis tests. Uroporphyrin results did not differ significantly between the subgroups
studied. Copro and uro + copro porphyrins were significantly different for smokers (P = 0.008) and occupational activities (P =
0.004). With respect to alcohol consumption, only men drinking >20 g/week showed significant differences in the levels of copro
(P = 0.022) and uro + copro porphyrins (P = 0.012). The 2.5-97.5th percentile limit values, excluding those for subjects with an
alcohol drinking habit >20 g/week, were 0-20.8, 11.7-93.1, and 15.9-102.9 μg/g creatinine for uro, copro and uro + copro
porphyrins, respectively. These percentile limit values can be proposed as a first attempt to provide urinary porphyrin reference
values for our population, serving for an early diagnosis of porphyrinopathies or as biomarkers of exposure to porphyrinogenic
agents.
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Introduction
Porphyrins are intermediates of the heme biosynthesis
pathway, ranging from eight to four carboxyl groups known
as uroporphyrin (8-carboxyl), hepta, hexa, penta, and cop-
roporphyrin (4-carboxyl), respectively (1). The predomi-
nant porphyrin in urine of healthy individuals is copropor-
phyrin (copro), followed by uroporphyrin (uro) at minor
concentrations (2). Porphyrias are inherited or acquired
metabolic disorders whose clinical cutaneous, neurologic or
visceral manifestations are related to characteristic patterns
of overproduction of specific heme precursors. There are
eight known enzymes involved in heme biosynthesis and
enzymatic defects in any subsequent step lead to an exces-
sive excretion of porphyrins and/or their precursors (3).
When clinically active, and in some cases even when latent
or in clinical remission, porphyrias induce high levels of
heme precursors in blood, urine, and/or stool (1).
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Some of the inherited porphyrias occur predominantly
as toxicogenetic conditions in which the genetic trait is
latent until clinical manifestations of porphyria are trig-
gered idiosyncratically by external factors (1,4). These
conditions have been observed after exposure to chemi-
cals such as polychlorinated biphenyls (5), hexachloro-
benzene (6), pentachlorophenol (1,7), and dioxins (8) and
heavy metals such as arsenic (9,10), Hg (3), and Pb (11).
They can also occur in individuals infected by some vi-
ruses such as HBV (12), HCV (12-14), and HIV (15,16) or
exposed to illicit or therapeutic drugs like alcohol (17), to
prolonged therapeutic use of estrogens (18) and to iron
overload (13), and as adverse effects of drugs like anticon-
vulsants (19) and anesthetics (20). In addition, these fac-
tors can cause porphyrias in individuals with no docu-
mented genetic predisposition as an acquired toxin-in-
duced condition (1,4).
Porphyria cutanea tarda is the most common of human
porphyrias and results from partial deficiency of the en-
zyme uroporphyrinogen decarboxylase producing the ac-
cumulation of uro and heptacarboxylporphyrins and a pre-
dominance of cutaneous symptomatology. It can result
from inherited or acquired conditions or a mixture of both
(21).
Disturbances of heme synthesis are associated with
alterations of subcellular structure and function that can be
related to the clinical signs and symptoms of porphyrias
and produce characteristic changes in heme-precursor
excretion. These measurable changes offer potential bio-
logical markers for detecting the harmful effects of specific
chemical exposure while their biological effects are still
preclinical and potentially reversible (1,5). However, most
clinicians, including specialists in occupational and envi-
ronmental medicine, are relatively uninformed about these
phenomena (1).
Urinary porphyrin excretion is the key tool for the diag-
nosis of disorders of the heme biosynthesis pathway and,
although several spectrofluorometric techniques are avail-
able they are not sensitive enough to detect the five
fractions (22). Therefore, the method of choice to deter-
mine urinary porphyrin fractions is gradient RP-HPLC us-
ing C18 columns with fluorescence detection (22). In addi-
tion to methodological limitations, the interpretation of any
laboratory test for porphyrins can be affected by personal
factors such as gender, age, occupational activity, smok-
ing and drinking habits (1).
The purpose of the present study was to determine the
normal range values for uro, copro, and uro + copro
porphyrin/creatinine ratio in urine samples from healthy
volunteers to provide a tool for the early diagnosis of
porphyrinopathies and for use as biomarkers of exposure
to porphyrinogenic agents.
Material and Methods
Study population and data collection
A total of 141 volunteers of both genders aged 18 to 65
years old, living in São Paulo city, Brazil, were screened
from 2003 to 2005. Individuals in the sample were ran-
domly selected from 12,500 workers of a tertiary university
hospital. The institutional Research Ethics Committee re-
viewed and approved the research protocol and all volun-
teers gave written informed consent to participate in the
study.
Exclusion criteria were: reported hereditary hemoglo-
binopathies, liver or kidney diseases (1); altered param-
eters in urinalysis (qualitative and quantitative analysis of
urinary elements) (23); or urinary creatinine values below
0.3 g/L, according to WHO recommendations for the ad-
justment of biological urinary indicators (24).
Fifteen volunteers were excluded from the study for the
following reasons: one for hereditary hemoglobinopathy,
which is a known cause of secondary coproporphyrinuria
(1); two for presenting urinary creatinine below 0.3 g/L,
considered too diluted for proper analysis (24), and the
remaining 12 volunteers for abnormal urinalysis results
according to NCCLS standards (23).
Urinary samples were collected according to standard
techniques in the early morning, into polypropylene flasks
protected from light. Samples were then separated into
two aliquots, one of which was immediately alkalinized
with sodium bicarbonate and stored under refrigeration (2-
8°C) until porphyrin analysis. The adjustment of concen-
tration-dilution of the spot urine sample was carried out by
determining urinary creatinine in the remaining aliquot by
the method of Jaffe, as described by Heinegard et al. (25).
All subjects were also requested to fill out a standard-
ized questionnaire to obtain information about age, place
of residence, type of work (technical or administrative),
food intake, personal habits (smoking, alcohol intake and
hobby activities) and exposure to pharmaceutical drugs in
order to provide baseline data for analysis of the risk of the
presence of porphyrin in urine.
Urinary porphyrin analysis
Urinary porphyrins and their homologues were ana-
lyzed by a high-performance liquid chromatography (HPLC)
protocol adapted from the method described by Sunyer et
al. (6), and published by Alves et al. (26) as described
below. Chemicals used for buffered phase preparation
were of analytical grade. Ammonium acetate, acetic acid
and methanol were purchased from Merck AG (Germany).
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Water was purified using a Milli-Q system from Millipore
(USA). Porphyrin standards and controls were purchased
from Immundiagnostik (Germany).
Briefly, a 2-mL urine sample was acidified with 70 μL
HCl and a 100-μL aliquot was injected into a modular
HPLC apparatus (Shimadzu Co., Japan) after 10-min cen-
trifugation at 1500 g and filtration through a 0.45-μm Milli-
pore filter. The HPLC system consisted of two high-pres-
sure pumps (LC-10AD), gradient controller (SCL-10A),
auto-sampler (SIL-10A), and fluorescence detector (RF-
535, excitation: 400 nm and emission: 620 nm). The sensi-
tivity of the method was 8.0 μg/L for each porphyrin homo-
logue.
All porphyrins were separated on a Lichrosphere 100-
RP column (125 x 4 mm) guarded by a Lichrosphere 100-
RP (4 x 4 mm) precolumn, both with a particle size of 5 μm
and purchased from Merck AG. Flow rate was 1 mL/min.
Separation conditions for optimized gradient elution of
porphyrins were as follows: mobile phase A consisting of
1.0 M ammonium acetate, pH 4.0, and mobile phase B
consisting of 100% methanol. The gradient program for
phase B was as follows: isocratic 10% B during the first
minute, linear increase from 10 to 95% in the subsequent
12 min and linear decrease from 95 to 10% in the last 3
min.
Statistical analysis
Associations of urinary concentrations of uro, copro
and uro + copro porphyrins with the independent variables
age, gender, occupational activity, and
smoking and drinking habits were ana-
lyzed statistically by Mann-Whitney and
Kruskal-Wallis tests, when applicable
(27,28). Bonferroni multiple compari-
son was further applied to the variables
with a significant difference by the Krus-
kal-Wallis test. The level of significance
was set at 0.05 and analyses were per-
formed with the Statistical Package for
the Social Sciences (SPSS), version
10.0.
Results
After exclusion criteria were applied
with 15 volunteers being excluded, the
remaining 126 subjects constituted the
study sample (67 women and 59 men).
Table 1 describes their demographic
characteristics and alcohol intake and
smoking habits.
Overall mean ± SD values for uro, copro, and uro +
copro porphyrins reported as μg/g urinary creatinine were
5.3 ± 6.0, 42.8 ± 26.4, and 48.1 ± 27.7 μg/g, respectively.
Only uro and copro porphyrin fractions could be quantified,
with uro + copro porphyrins reported by their sum. Table 2
shows the median, 25-75% range and P values for uro,
copro, and uro + copro porphyrins stratified by age, gen-
der, occupational activity, and smoking and drinking hab-
its.
Figure 1 shows the total distribution of uro, copro, and
uro + copro porphyrins values stratified for the variables
with significant differences in Table 2 (professional activ-
ity, smoking and drinking habits). Hospital laboratory em-
ployees involved in technical activities, when compared to
those with administrative functions, presented higher con-
centrations of urinary copro (median 45.5 vs 30.5 μg/g
creatinine, P = 0.004) and uro + copro porphyrins (median
47.3 vs 34.9 μg/g creatinine, P = 0.007). Smokers pre-
sented lower values than non-smokers for copro (median
22.5 and 37.2 μg/g creatinine, P = 0.008) and uro + copro
porphyrins (median 27.2 and 43.5 μg/g creatinine, P =
0.019). With respect to alcohol consumption, only men
showed statistically significant differences (see Table 3
and Figure 1) in the levels of copro (P = 0.022) and uro +
copro porphyrins (P = 0.012). Bonferroni analysis of these
differences showed that individuals with an alcohol con-
sumption >20 g/week had higher copro porphyrin levels
compared to those with an alcohol consumption ≤20 g/
week (P = 0.047) and to those with no alcohol consumption
Table 1. Demographic data of the subjects studied.
Males (N = 59) Females (N = 67) Total (N = 126)
Age (years) 39.5 ± 6.0 40.9 ± 6.2 40.2 ± 6.1
Range 19-59 18-65 18-65
18-40 years old 30.1 ± 6.2 33.5 ± 5.5 31.8 ± 5.9
(N = 41) (N = 31) (N = 72)
>40 years old 48.9 ± 5.8 48.2 ± 6.9 48.6 ± 6.4
(N = 18) (N = 36) (N = 54)
Occupational activity (N)
Technicians 16 43 59
Management 43 24 67
Smoking habit (N)
Non-smokers 53 56 109
Smokers 6 11 17
Drinking habit (N)
None 18 24 42
≤20 g/week 32 42 74
>20 g/week 9 1 10
Age is reported as means ± SD. Occupational activity, smoking and drinking habit are
reported as number of subjects (N).
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Table 2. Median and 25th-75th percentiles for uro, copro, and uro + copro porphyrins (μg/g creatinine) and P value for subjects divided
into subgroups.
Groups Uro Copro Uro + copro
Median 25-75 Median 25-75 Median    25-75
Age
≤40 years old (N = 72) 5.6 0-7.9 33.6 20.9-56.8 40.0 25.1-60.1
>40 years old (N = 54) 5.0 0-9.8 38.4 24.1-62.4 42.6 28.7-70.9
Gender
Females (N = 67) 4.6 0-9.4 34.8 23.3-56.4 42.9 28.5-65.0
Males (N = 59) 4.7 0-8.0 33.8 19.5-59.6 40.8 23.0-64.0
Occupational activity
Management (N = 67) 4.6 0-8.0 30.5* 19.0-52.3 34.9* 23.5-53.5
Technicians (N = 59) 5.7 0-9.3 45.5 28.7-69.4 47.3 31.4-78.0
Smoking habit
No (N = 109) 4.6 0-8.8 37.2* 23.4-59.6 43.5* 28.3-64.3
Yes (N = 17) 7.2 0-11.1 22.5 13.0-36.4 27.2 20.1-40.6
Drinking habit/alcohol consumed in a week (g)
0 (N = 42) 5.7 0-9.5 33.6 23.4-54.3 39.0 28.5-57.0
≤20.0 g per week (N = 74) 4.5 0-8.3 31.2 21.2-56.5 40.5 26.2-60.0
>20.0 g per week (N = 10) 4.3 0-8.6 70.6 30.3-94.1 75.8 37.1-106.2
Total (N = 126) 4.7 0-8.9 34.0 22.4-59.8 48.1 27.4-65.4
Comparisons were made by the Mann-Whitney test except when otherwise indicated and asterisks denote P < 0.05. Individuals were
classified as smokers if smoking >5 cigarettes/day. The Kruskal-Wallis test was used to analyze data for alcohol intake.
Figure 1. Box-and-whisker plot for urinary levels of uro, copro, and uro + copro porphyrins according to occupational activity and
smoking and drinking habits (126 individuals, São Paulo, SP, Brazil). Points are outliers, the box indicates the interquartile range, the
whiskers indicate the range, and the horizontal line within the box is the median.
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at all (P = 0.012). The latter two groups did not differ
significantly from one another (see Table 3). The same
behavior was observed for uro + copro porphyrins, with
men with an alcohol consumption >20 g/week having
higher levels than those with an alcohol consumption ≤20
g/week (P = 0.038) and those with no alcohol consumption
at all (P = 0.009). Again, the latter two groups showed no
statistical difference from one another (see Table 3).
Due to the non-normal distribution of the uro and copro
fractions, the 95% confidence intervals (95%CI) were de-
termined by cutting off the 2.5 and 97.5% percentiles, as
recommended by Apostoli (29). The 2.5-97.5th percentiles
obtained, excluding subjects who reported more than 20 g/
week of alcohol consumption, were: 0-20.8 μg/g creatinine
for uro, 11.7-93.1 creatinine for copro, and 15.9-102.9 μg/
g creatinine for uro + copro porphyrins.
Discussion
The aim of the present investigation was to determine
the characteristic profile of urinary porphyrins in spot urine
samples from a normal population in order to establish
reference values and, therefore, to provide tools for an
early diagnosis of porphyrinopathies and to allow the use
of these values as biomarkers of exposure to porphyrino-
genic agents. Urinary excretion of porphyrins in spot uri-
nary samples has been shown to reflect total daily excre-
tion, avoiding the problems of collecting 24-h specimens
(30). Since porphobilinogen can polymerize to porphyrin
or be non-enzymatically converted to porphyrins, it is very
important to protect urine samples from light and to store
them between 2 and 8°C (2).
Our sample represented a population of highly hetero-
geneous ethnic origin, as is usual in Brazil. The State of
São Paulo receives migrants from different parts of the
country, and people of European, Mediterranean, African,
and Asian origin are common. Thus, ours was a multiethnic
sample living in a city with high-density traffic and in which
air pollution is of particular concern, with carbon monoxide,
sulfur, nitrogen dioxides, and particulate material meas-
ured daily around the city by the São Paulo State Sanitary
Agency (CETESB, 2005), and being frequently above the
recommended levels (31). Although, to the best of our
knowledge, there are no published reports relating air
pollutants to urinary porphyrin excretion, we believe that a
description of the ethnic and environmental background of
our sample would be important for future comparisons with
other published results.
The size of our sample (126) met the requirements of
the International Federation of Clinical Chemistry (IFCC)
(32) and Clinical and Laboratory Standards Institute (CLSI)
(33) that recommend at least 120 individuals to estimate
the reference range and 95%CI for a new laboratory value
to be applied to a healthy population.
Of the five porphyrin fractions known, we were able to
quantitatively measure only uro and copro porphyrins in
spot urinary samples. The fraction with 7 carboxyl groups
was detected in 21/126 individuals (16.5%) of our sample,
Table 3. Median and interquartile interval (25-75%) for urinary copro and uro + copro porphyrins (μg/g creatinine) in male subjects
classified into subgroups according to alcohol consumption per week.
Kruskal-Wallis test
Alcohol consumption per week Copro Uro + copro
Median 25-75 P Median 25-75 P
0 g (N = 18) 30.0 16.6-34.1 34.3 18.4-40.4
≤20 g (N = 32) 35.0 20.8-55.9 0.022 41.4 24.7-59.9 0.012
>20 g (N = 9) 76.3 42.7-90.6 86.7 46.6-104.4
Bonferroni test
Group comparisons Copro Uro + copro
Median difference P Median difference P
0 vs ≤20 g -8.1 1.0 -9.1 0.94
0 vs >20 g -35.4 0.012 -38.2 0.009
≤20 vs >20 g -27.3 0.047 -29.2 0.038
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but its values were below the quantification limit as were
fractions with 6 and 5 carboxyl groups. Similar findings
have been reported by Sunyer et al. (6), who found the
hepta fraction in only 7% of their subjects and also did not
detect the other fractions.
Our findings for uro (5.3 ± 6.0 μg/g creatinine), copro
(41.0 ± 25.2 μg/g creatinine) and uro + copro porphyrins
(46.2 ± 26.3 μg/g creatinine) agree with the data reported
by Buratti et al. (34) for total porphyrins. Apostoli et al. (10)
detected higher values for uro, copro, and uro + copro
porphyrins, namely 9.4 ± 11.4, 70.5 ± 36.7, and 89.8 ±
44.8, respectively, using analytical methodology similar to
that which we used. The differences found could, there-
fore, be attributed to the different populations studied.
We found no gender differences in urinary porphyrin
profiles, also in agreement with other published reports
(35).
We found that smokers had lower copro and uro +
copro porphyrin levels (Table 2). However, since only
13.5% of our sample smokes, and there are no published
data relating changes in urinary porphyrin excretion to
smoking habit, we believe that further studies are needed
in order to properly address these findings. Nevertheless,
it has been reported that benzopyrene derivatives pre-
sented in cigarette smoke can interfere with CYP 450,
inducing higher activation of that enzymatic system (36).
Santos et al. (37) found a significant association be-
tween alcohol intake and porphyrinuria in non-porphyric
adults. Alcohol consumption may trigger a hidden heredi-
tary (or non-hereditary) predisposition to a condition of
altered porphyrin metabolism or of overt hepatic porphyria
(17).
We excluded individuals reporting an alcohol consump-
tion >20 g/week from the calculation of the 95%CI pre-
sented in this study in order to obtain a proper definition of
what could be thought to be the upper reference value for
a normal population.
To define new normal laboratory profiles for healthy
individuals, establishing reference values related to gen-
der, age and personal habits, plays an important role in
population medicine. Furthermore, these values are re-
quired for assessing the health status of patients (29) and
are a basic tool for biomonitoring programs in occupational
and environmental medicine (34).
Laboratory test results can, in general, be compro-
mised by a variety of factors, including specimen integrity
(reflecting conditions of specimen collection, processing,
transport and storage), analytical quality control practices
and limitations of the analytical methods (37). Sample
protection from light is very important for porphyrin analy-
sis since the fluorescence of porphyrins can decrease if
exposed to light (4).
Although urinary porphyrins are a highly sensitive and
specific biomarker for altered heme biosynthesis, they lack
specificity for identifying the enzyme, co-factor, etc. re-
sponsible for this metabolic alteration. In such cases,
some enzyme activities of the heme biosynthetic pathway
must be quantified and/or the possible porphyrinogenic
agent implicated should be investigated.
The aim of this study was to establish reference values
for a healthy population. However, the sample used, 126
subjects, was not large enough to allow multivariate anal-
ysis of risk factors associated with alterations in urinary
porphyrin excretion. Thus, the study of more subjects will
provide more information on other possible risk factors for
an altered spot urinary porphyrin profile.
Finally, although the present results were derived only
from a sample of the São Paulo city population, we believe
they can be used to provide tentative reference levels for
other regional studies in Brazil or other countries, and to
serve as a proxy to detect slight, but sometimes irrevers-
ible, changes in heme biosynthesis.
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